Related Experiment Video

Updated: May 12, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
08:55

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia

Published on: November 30, 2016

[Role of Activin A and Myostatin in cancer cachexia]

Jean-Paul Thissen1, Audrey Loumaye

  • 1Pôle d'endocrinologie, diabétologie et nutrition (EDIN), institut de recherches expérimentales et cliniques (IREC), secteur des sciences de la santé (SSS), université catholique de Louvain, avenue Hippocrate, B1.55.06, 1200 Bruxelles, Belgique. jeanpaul.thissen@uclouvain.be

Annales D'Endocrinologie
|April 10, 2013
PubMed

Insights

Activin A (ActA) and Myostatin (Mstn) produced by cancers may cause muscle wasting (cachexia) and death. Inhibiting these proteins, particularly with sActRIIB, shows promise for treating cancer-related muscle atrophy.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Context:

  • Cancer cachexia is a complex metabolic syndrome leading to significant muscle loss and mortality.
  • Activin A (ActA) and Myostatin (Mstn), members of the TGF-β superfamily, are implicated in muscle wasting.
  • Human tumoral cell lines secrete ActA and Mstn, suggesting a potential role in cancer progression.

Purpose:

  • To investigate the role of Activin A (ActA) and Myostatin (Mstn) in cancer-associated skeletal muscle atrophy.
  • To explore the therapeutic potential of ActA and Mstn antagonists in mitigating cancer cachexia.

Summary:

  • Systemic administration of ActA and Mstn induces muscle atrophy in mice.
  • Inhibin-α knockout mice with elevated ActA levels exhibit muscle atrophy and cachexia.
  • Antagonists targeting ActA and Mstn prevent muscle atrophy and mortality in animal tumor models.
  • Cancer cell-derived ActA or Mstn may drive cachexia and mortality in human cancers.

Impact:

  • These findings suggest ActA and Mstn as potential therapeutic targets for cancer cachexia.
  • The development of ActA and Mstn inhibitors, such as sActRIIB, offers a promising avenue for clinical intervention.
  • Understanding the molecular mechanisms of cancer-induced muscle atrophy can lead to improved patient outcomes and reduced mortality.

More Related Videos

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines06:00

Development of a Human Preclinical Model of Osteoclastogenesis from Peripheral Blood Monocytes Co-cultured with Breast Cancer Cell Lines

Published on: September 13, 2017

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...